课题基金 / 基金详情

项目摘要

项目成果

Richard H Gomer的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract Fibrosing diseases such as pulmonary fibrosis are associated with up to 45% of the deaths in the US. In these diseases, inappropriate scar tissue called fibrotic lesions forms in internal organs. There are no FDA- approved therapies that reverse fibrosis, and much remains to be known about mechanisms driving fibrosis. In fibrotic lesions in mouse and human lungs, there is an increase in the levels of sialidases, enzymes that remove sialic acids from the distal tips of extracellular glycoproteins and other glycoconjugates. Sialidases appear to potentiate fibrosis at least in part by increasing levels of the pro-fibrotic cytokine TGF-β1 produced by some immune system cells. Conversely, TGF-β1 causes lung epithelial cells, lung fibroblasts, and some immune system cells to upregulate sialidases. Our hypothesis is that fibrosis is driven in part by a runaway positive feedback loop where sialidase potentiates fibrosis and fibrosis potentiates sialidase. In support of this hypothesis, we found that injections of two different sialidase inhibitors reduce pulmonary fibrosis in the mouse bleomycin model. To gain insight into what appears to be a fundamental mechanism linking the immune system to lung epithelial cells and fibroblasts, as well as a mechanism that helps drive fibrosis, we propose three specific aims. Since identifying the key sialidase(s) that is/are upregulated in fibrosis will identify potential targets to inhibit fibrosis, our first aim is to test the hypothesis that a sialidase called NEU3 is the major sialidase that potentiates fibrosis. Our second aim is to determine which immune system cells respond to sialidases and elucidate the receptor(s) whereby immune system cells sense the upregulated sialidases, and thus identify potential targets to block the feedback loop. Our third aim is to determine how sialidases cause an upregulation of TGF-β1, thus essentially working backwards on the sialidase sensing pathway toward the Aim 2 work. Together, this work will help to elucidate a novel mechanism that regulates the innate immune system and fibrosis, and may lead to new therapies for fibrosing diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidation of a Eukaryotic Chemorepulsion Mechanism
  • 批准号:
    10318611
  • 项目类别:
  • 资助金额:
    $36.4万
  • 财政年份:
    2021
  • 负责人:
    Richard H Gomer
  • 依托单位:
Elucidation of a Eukaryotic Chemorepulsion Mechanism
  • 批准号:
    10541123
  • 项目类别:
  • 资助金额:
    $36.33万
  • 财政年份:
    2021
  • 负责人:
    Richard H Gomer
  • 依托单位:
Genetic suppression of loss of TPP1
  • 批准号:
    9477794
  • 项目类别:
  • 资助金额:
    $17.36万
  • 财政年份:
    2017
  • 负责人:
    Richard H Gomer
  • 依托单位:
Genetic suppression of loss of TPP1
  • 批准号:
    9372001
  • 项目类别:
  • 资助金额:
    $21.8万
  • 财政年份:
    2017
  • 负责人:
    Richard H Gomer
  • 依托单位:
国内基金
海外基金
基于聚金属氧酸盐对Amyloid蛋白的定点化学修饰及其在阿尔茨海默症治疗中的应用
  • 批准号:
    22077118
  • 项目类别:
    面上项目
  • 资助金额:
    63.0万元
  • 批准年份:
    2020
  • 负责人:
    高楠
  • 依托单位:
基于S1P通路探究Amyloid-β在干性年龄相关性黄斑变性中的作用
  • 批准号:
    81870666
  • 项目类别:
    面上项目
  • 资助金额:
    57.0万元
  • 批准年份:
    2018
  • 负责人:
    王海燕
  • 依托单位:
Amyloid-beta-PirB 相互作用介导小胶质细胞表型和功能变化参与AD进展的机制研究
  • 批准号:
    81601123
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    17.0万元
  • 批准年份:
    2016
  • 负责人:
    都瑾
  • 依托单位:
Beta-amyloid寡聚体特有的抗原表位多肽疫苗的研究
  • 批准号:
    30971012
  • 项目类别:
    面上项目
  • 资助金额:
    35.0万元
  • 批准年份:
    2009
  • 负责人:
    刘瑞田
  • 依托单位: